Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC

Apoptosis

Volumn 19, Issue 11, 2014, Pages 1627-1636

  Hu, Yuan ^a   Hong, Yin ^a   Xu, Yuanjie ^a   Liu, Ping ^a   Guo, Dai Hong ^a   Chen, Yibang ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; JAK STAT; Non small cell lung cancer; Resistance

Indexed keywords

CASPASE 3; CISPLATIN; JANUS KINASE 2; RUXOLITINIB; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; JAK2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION ASSAY; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; IC50; MONOTHERAPY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HETEROGRAFTS; HUMANS; JANUS KINASE 2; LUNG NEOPLASMS; MICE, NUDE; PHOSPHORYLATION; PYRAZOLES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84910144414     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-014-1030-z     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
2. Lerouge D, Riviere A, Dansin E et al (2014) A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer 14:231
3. Jakopovic M, Thomas A, Lopez-Chavez A (2014) From platinum compounds to targeted therapies in advanced thoracic malignancies. Anticancer Res 34:477-482
4. A-MFaD Büsselberg (2011) Cisplatin as an Anti-Tumor Drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancer 3:1351-1371
5. D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2012) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v116-v119
6. d'Amato TA, Landreneau RJ, Ricketts W et al (2007) Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 133:352-363
7. Bunn PA Jr (2005) Platinums in lung cancer: sufficient or necessary? J Clin Oncol 23:2882-2883
8. Yao X, Zhu F, Zhao Z, Liu C, Luo L, Yin Z (2011) Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway. J Cell Biochem 112:2837-2849
9. Tezcanli Kaymaz B, Bozok Cetintas V, Eroglu Z, Kosova B (2014) Suppression of STAT3 by chemically modified siRNAs increases the chemotherapeutic sensitivity of parental and cisplatin-resistant non-small cell lung cancer cells. J BUON 19:145-152
10. Lai SY, Johnson FM (2010) Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat 13:67-78
11. Barre B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O (2007) The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 13:4-11
12. Catlett-Falcone R, Dalton WS, Jove R (1999) STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol 11:490-496
13. Govindan R, Ding L, Griffith M et al (2013) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150:1121-1134
14. Becker H, Engelhardt M, von Bubnoff N, Wasch R (2014) Ruxolitinib. Recent Results Cancer Res 201:249-257
15. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
16. Csizmadia E, Csizmadia V (2009) Detection of apoptosis in tissue sections. Methods Mol Biol 559:49-63
17. Solomon B, Bunn PA Jr (2007) Adjuvant chemotherapy for non-small cell lung cancer. Cancer Invest 25:217-225
18. Coxon A, Ziegler B, Kaufman S et al (2012) Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer 11:70
19. Sims JT, Ganguly S, Fiore LS, Holler CJ, Park ES, Plattner R (2009) STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner. Biochem Pharmacol 78:249-260
20. Jatiani SS, Baker SJ, Silverman LR, Reddy EP (2010) Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 1:979-993
21. Ueda F, Sumi K, Tago K, Kasahara T, Funakoshi-Tago M (2013) Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs. Cell Signal 25:2115-2124
22. Abe M, Funakoshi-Tago M, Tago K et al (2009) The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice. Int Immunopharmacol 9:870-877
23. Funakoshi-Tago M, Pelletier S, Moritake H, Parganas E, Ihle JN (2008) Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol 28:1792-1801
24. Song H, Sondak VK, Barber DL, Reid TJ, Lin J (2004) Modulation of Janus kinase 2 by cisplatin in cancer cells. Int J Oncol 24:1017-1026
25. Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R (2005) A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 280:32979-32988
26. Turkson J, Zhang S, Palmer J et al (2004) Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3:1533-1542
27. Thoennissen NH, Iwanski GB, Doan NB et al (2009) Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 69:5876-5884
28. Lorenzo HK, Susin SA (2004) Mitochondrial effectors in caspase-independent cell death. FEBS Lett 557:14-20
29. Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42-49
30. Kabeer FA, Sreedevi GB, Nair MS et al (2013) Antineoplastic effects of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber, on lung adenocarcinoma (A549) cells. J Integr Med 11:269-277
31. Wu ZZ, Lu HP, Chao CC (2010) Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem Pharmacol 80:262-276